EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of Natural Compounds as Potential FGFR2 Inhibitors in Cholangiocarcinoma via Virtual Screening and Network-Based Analysis

Duygu Sari-Ak, Nazli Helvaci, Fatih Con, Alev Kural

Pharmedicine Journal · 2025

DOI: 10.62482/pmj.28 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmedicine Journal, 2025. Verfasst von Duygu Sari-Ak und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cholangiocarcinoma is an aggressive neoplasm of bile duct epithelial cells with poor prognosis due to limited treatment options. Fibroblast growth factor receptor 2 (FGFR2) is critical in cholangiocarcinoma by activating pathways such as MAPK/ERK and PI3K/AKT, marking it as a promising therapeutic target. This study aimed to identify natural FGFR2 inhibitors by using computational methods.

Methods

46 natural compounds were selected from PubChem based on favorable physicochemical properties and drug-likeness criteria. Molecular docking was performed using SwissDock against FGFR2 (PDB ID: 4J97). The top five compounds were further assessed for pharmacokinetics, pharmacodynamics, and toxicity via SwissADME, pkCSM, and DeepPK tools. Additionally, protein-protein interaction networks and pathway enrichment analyses were conducted using the STRING database and KEGG.

Results

Docking analysis identified Rutecarpine, Palonosetron, Metribolone, 6-Ketoestradiol, and Gestrinone as the top FGFR2 inhibitors, with docking scores between – 6.34 and – 5.95 kcal/mol. ADMET predictions showed favorable drug- like properties, good bioavailability, and acceptable safety profiles. Network and pathway analyses confirmed FGFR2’s role in key oncogenic pathways, including MAPK, PI3K/AKT, and Ras.

Conclusions

This study identified promising FGFR2 inhibitors, particularly Rutecarpine, as potential therapeutic candidates for cholangiocarcinoma, warranting further experimental validation.

Zitieren

APA

Sari-Ak, D., Helvaci, N., Con, F., & Kural, A. (2025). Identification of Natural Compounds as Potential FGFR2 Inhibitors in Cholangiocarcinoma via Virtual Screening and Network-Based Analysis. Pharmedicine Journal. https://doi.org/10.62482/pmj.28

Vancouver

Sari-Ak D, Helvaci N, Con F, Kural A. Identification of Natural Compounds as Potential FGFR2 Inhibitors in Cholangiocarcinoma via Virtual Screening and Network-Based Analysis. Pharmedicine Journal. 2025. doi:10.62482/pmj.28

BibTeX
@article{SariAk2025,
  author = {Sari-Ak, Duygu and Helvaci, Nazli and Con, Fatih and Kural, Alev},
  title = {Identification of Natural Compounds as Potential FGFR2 Inhibitors in Cholangiocarcinoma via Virtual Screening and Network-Based Analysis},
  journal = {Pharmedicine Journal},
  year = {2025},
  doi = {10.62482/pmj.28}
}
Kostenlos starten →